| pubmed-article:19203723 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19203723 | lifeskim:mentions | umls-concept:C1257890 | lld:lifeskim |
| pubmed-article:19203723 | lifeskim:mentions | umls-concept:C0239307 | lld:lifeskim |
| pubmed-article:19203723 | lifeskim:mentions | umls-concept:C0005961 | lld:lifeskim |
| pubmed-article:19203723 | lifeskim:mentions | umls-concept:C0005767 | lld:lifeskim |
| pubmed-article:19203723 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:19203723 | lifeskim:mentions | umls-concept:C1527249 | lld:lifeskim |
| pubmed-article:19203723 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:19203723 | lifeskim:mentions | umls-concept:C0596545 | lld:lifeskim |
| pubmed-article:19203723 | lifeskim:mentions | umls-concept:C1705576 | lld:lifeskim |
| pubmed-article:19203723 | lifeskim:mentions | umls-concept:C0302189 | lld:lifeskim |
| pubmed-article:19203723 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:19203723 | lifeskim:mentions | umls-concept:C0449445 | lld:lifeskim |
| pubmed-article:19203723 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:19203723 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:19203723 | pubmed:dateCreated | 2009-2-10 | lld:pubmed |
| pubmed-article:19203723 | pubmed:abstractText | Reduced-intensity conditioning (RIC) regimens for allogeneic hematopoietic stem cell transplantation (HCT) allowed the existence of an allogeneic cell-mediated antitumor effect in metastatic colorectal cancer (mCRC) to be explored. We report on 39 patients with progressing mCRC treated with different RIC regimens in a multicenter clinical trial of the European Bone Marrow Transplantation Group. Disease status at transplant was progressive disease (PD) in 31 patients (80%), stable disease (SD) in 6 (15%), and partial response (PR) in 2 (5%). All patients engrafted (median donor T cell chimerism of 90% at day +60). Transplant-related morbidities were limited. Grades II-IV acute graft-versus-host disease (aGVHD) occurred in 14 patients (35%) and chronic GVHD (cGVHD) in 9 patients (23%). Transplant-related mortality occurred in 4 patients (10%). The best tumor responses were: 1 complete response (CR) (2%), 7 PR (18 %), and 10 SD (26%), giving an overall disease control in 18 of 39 patients (46%). Allogeneic HCT after RIC is feasible; the collected results compared favorably in terms of tumor response with those observed using conventional approaches beyond second-line therapies. The study of an allogeneic cell based therapy in less advanced patients is warranted. | lld:pubmed |
| pubmed-article:19203723 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19203723 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19203723 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19203723 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19203723 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:19203723 | pubmed:issn | 1523-6536 | lld:pubmed |
| pubmed-article:19203723 | pubmed:author | pubmed-author:RingdénOlleO | lld:pubmed |
| pubmed-article:19203723 | pubmed:author | pubmed-author:NiederwieserD... | lld:pubmed |
| pubmed-article:19203723 | pubmed:author | pubmed-author:HentschkePatr... | lld:pubmed |
| pubmed-article:19203723 | pubmed:author | pubmed-author:BarkholtLisbe... | lld:pubmed |
| pubmed-article:19203723 | pubmed:author | pubmed-author:AgliettaMassi... | lld:pubmed |
| pubmed-article:19203723 | pubmed:author | pubmed-author:CicconeGiovan... | lld:pubmed |
| pubmed-article:19203723 | pubmed:author | pubmed-author:CapaldiAntoni... | lld:pubmed |
| pubmed-article:19203723 | pubmed:author | pubmed-author:LeoneFrancesc... | lld:pubmed |
| pubmed-article:19203723 | pubmed:author | pubmed-author:EBMT Solid... | lld:pubmed |
| pubmed-article:19203723 | pubmed:author | pubmed-author:DemirerTanner... | lld:pubmed |
| pubmed-article:19203723 | pubmed:author | pubmed-author:OmazicBrigitt... | lld:pubmed |
| pubmed-article:19203723 | pubmed:author | pubmed-author:BertolderoGio... | lld:pubmed |
| pubmed-article:19203723 | pubmed:author | pubmed-author:SchiancaFabri... | lld:pubmed |
| pubmed-article:19203723 | pubmed:author | pubmed-author:CaravelliDani... | lld:pubmed |
| pubmed-article:19203723 | pubmed:author | pubmed-author:MinottoColudi... | lld:pubmed |
| pubmed-article:19203723 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19203723 | pubmed:volume | 15 | lld:pubmed |
| pubmed-article:19203723 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19203723 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19203723 | pubmed:pagination | 326-35 | lld:pubmed |
| pubmed-article:19203723 | pubmed:meshHeading | pubmed-meshheading:19203723... | lld:pubmed |
| pubmed-article:19203723 | pubmed:meshHeading | pubmed-meshheading:19203723... | lld:pubmed |
| pubmed-article:19203723 | pubmed:meshHeading | pubmed-meshheading:19203723... | lld:pubmed |
| pubmed-article:19203723 | pubmed:meshHeading | pubmed-meshheading:19203723... | lld:pubmed |
| pubmed-article:19203723 | pubmed:meshHeading | pubmed-meshheading:19203723... | lld:pubmed |
| pubmed-article:19203723 | pubmed:meshHeading | pubmed-meshheading:19203723... | lld:pubmed |
| pubmed-article:19203723 | pubmed:meshHeading | pubmed-meshheading:19203723... | lld:pubmed |
| pubmed-article:19203723 | pubmed:meshHeading | pubmed-meshheading:19203723... | lld:pubmed |
| pubmed-article:19203723 | pubmed:meshHeading | pubmed-meshheading:19203723... | lld:pubmed |
| pubmed-article:19203723 | pubmed:meshHeading | pubmed-meshheading:19203723... | lld:pubmed |
| pubmed-article:19203723 | pubmed:meshHeading | pubmed-meshheading:19203723... | lld:pubmed |
| pubmed-article:19203723 | pubmed:meshHeading | pubmed-meshheading:19203723... | lld:pubmed |
| pubmed-article:19203723 | pubmed:meshHeading | pubmed-meshheading:19203723... | lld:pubmed |
| pubmed-article:19203723 | pubmed:meshHeading | pubmed-meshheading:19203723... | lld:pubmed |
| pubmed-article:19203723 | pubmed:meshHeading | pubmed-meshheading:19203723... | lld:pubmed |
| pubmed-article:19203723 | pubmed:meshHeading | pubmed-meshheading:19203723... | lld:pubmed |
| pubmed-article:19203723 | pubmed:meshHeading | pubmed-meshheading:19203723... | lld:pubmed |
| pubmed-article:19203723 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19203723 | pubmed:articleTitle | Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience. | lld:pubmed |
| pubmed-article:19203723 | pubmed:affiliation | Division of Medical Oncology, Department of Oncological Sciences, Institute for Cancer Research and Treatment, Candiolo and University of Torino Medical School, Turin, Italy. | lld:pubmed |
| pubmed-article:19203723 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19203723 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:19203723 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:19203723 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19203723 | lld:pubmed |
